Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Overview

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Full Title of Study: “A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: January 14, 2021

Detailed Description

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 study in subjects with moderate to severe Hidradenitis Suppurativa. The study is multicenter and will consist of three subject groups. Subjects will be randomized 1:1:1 to a treatment of 10mg avacopan twice daily, 30 mg avacopan twice daily or placebo twice daily for 12 weeks. Following the 12 weeks double-blind treatment period, subjects on placebo will be re-randomized 1:1 to receive 10 mg or 30 mg avacopan twice daily for additional 24 weeks. Subjects treated with avacopan will continue to receive the same dose (either 10 mg or 30 mg twice daily) for additional 24 weeks. Subjects will be on study treatment for 36 weeks and will be followed for 44 weeks for assessment of safety and efficacy. Primary efficacy analysis will be at 12 weeks.

Interventions

  • Drug: Avacopan
    • Active treatment
  • Other: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Placebo Comparator: Group A
    • Placebo twice daily (BID) for Period 1 of the study
  • Experimental: Group B
    • Avacopan 10 mg twice daily (BID) for Period 1+2 of the study
  • Experimental: Group C
    • Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
  • Experimental: Placebo to Avacopan 10 mg
    • Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
  • Experimental: Placebo to Avacopan 30 mg
    • Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.
    • Time Frame: Baseline to Week 12
    • The percentage of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 in the ITT1 population using the NRI-CMH Test. A response was defined as a reduction of at least 50 in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count compared with baseline. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. NRI- non-responder imputation; CMH- Cochran-Mantel-Haenszel. Percentage values have been reported as opposed to proportion values to allow for statistical analyses.

Secondary Measures

  • Change From Baseline in Total AN Count at Week 12
    • Time Frame: Baseline to Week 12
    • The Change from Baseline in total AN (abscess and inflammatory nodule) count at Week 12 using MMRM and OC in the ITT1 population. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. MMRM – mixed effects model for repeated measures; OC- observed case
  • Number of Responders Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in the Subject’s Global Assessment of Skin Pain (NRS30) in Subjects With a Baseline NRS of at Least 3, Evaluated at Week 12
    • Time Frame: Baseline to Week 12
    • NRS30 = The number of responders achieving at least 30% reduction and at least 1 unit reduction from baseline in the subject’s global assessment of skin pain score. Percentage is based on the number of subjects with a baseline pain score of at least 3 in each treatment group. Weekly averages of daily pain will be calculated based on subjects’ daily diary recording of the worst pain experienced in the previous 24 hours. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. NRI- non-responder imputation
  • Area Under the Curve From Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 Plasma Concentration on Day 1
    • Time Frame: Day 1
    • The Area under the curve from Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 plasma concentration on Day 1 in the PK population. PK- pharmacokinetics
  • Number of Responders With Baseline Hurley Stage II Who Achieved an AN Count of 0, 1, or 2 at Week 12
    • Time Frame: Baseline and Week 12
    • The number of responders With Baseline Hurley Stage II Who Achieved an Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12 using the NRI-CMH Test in the ITT1 population. Hurley Stage II disease is defined as having 1 or more widely separated recurrent abscesses with tract formation and scars. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.
  • Change of IHS4 Score Relative to Baseline at Week 12.
    • Time Frame: Baseline and Week 12
    • The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1. IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS. IHS4- International HS Severity Scoring System
  • Change From Baseline in Inflammatory Nodule Count at Week 12
    • Time Frame: Baseline and Week 12
    • A reduction in AN signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.
  • Change From Baseline in Abscess Count at Week 12
    • Time Frame: Baseline and Week 12
    • A reduction in abscess count signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.
  • Change From Baseline in Draining Fistula Count at Week 12
    • Time Frame: Baseline and Week 2, Week 4, Week 8 and Week 12
    • The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.
  • Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS
    • Time Frame: Baseline and Week 2, Week 4, Week 8 and Week 12
    • Twelve body areas will be evaluated to calculate the Sartorius and modified Sartorius scores: left and right axillae, left and right inframammary areas, intermammary area, left and right buttocks, left and right inguinocrural folds, perianal area, perineal area, and other. The presence of nodules, abscesses, fistulae, scars, and other findings will be recorded. The longest distance between two lesions and whether lesions are separated by normal skin is recorded. A score of 4 indicates the least severe disease, and higher scores indicate increasingly severe disease. There is no upper limit in the score. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Participating in This Clinical Trial

Inclusion Criteria

  • At least 18 years of age – Clinical diagnosis of HS (Hurley Stage II or III), confirmed by a dermatologist, for at least 6 months prior to Screening – HS lesions are present in at least 2 distinct anatomic areas – Inadequate or loss of response to a systemic course of antibiotics typically of at least 90 days – Must have at least 5 inflammatory nodules or abscesses at screening – Use adequate birth control for subject and partners of child bearing potential – Willing and able to give written Informed Consent Exclusion Criteria:

  • Pregnant or breast-feeding – Any other skin disease that may interfere with the assessment of HS – Rapidly progressive, expanding HS within 30 days prior to screening – More than 20 draining fistulae at screening – Any anti-TNF-α treatment for HS or for other conditions prior to Day 1 visit will be prohibited. Exception: Subjects who were previously treated with an anti-TNF-α drug and discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment – Systemic antibiotics are generally excluded – Topical antibiotics use within 14 days prior to Day 1 is excluded – Have started a topical prescription medicine for HS within 14 days prior to screening – A systemic medicine for HS, including biologics and other systemic therapies – Have received within 14 days prior to Day 1 visit or is expected to require oral or transdermal opioid analgesics (except for tramadol) for any reason

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ChemoCentryx
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • ChemoCentryx Inc, Study Director, ChemoCentryx Inc

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.